News Quantified

MRUS – merus n.v. - common shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Merus N.V. (MRUS): A Bull Case Theory [Yahoo! Finance]

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab [Yahoo! Finance]

Merus (NASDAQ:MRUS) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.

Merus (NASDAQ:MRUS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

-2.8%

MISS

BMO Capital Markets

Leerink Partners

Form 4 Merus N.V. For: Dec 18 Filed by: GENMAB A/S

Form SCHEDULE 13D Merus N.V. Filed by: GENMAB A/S

Form 4 Merus N.V. For: Dec 16 Filed by: GENMAB A/S

Form 3 Merus N.V. For: Dec 12 Filed by: GENMAB A/S

Form 4 Merus N.V. For: Dec 12 Filed by: PERRY GREGORY D

Top News Gainers

3/12 Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update 34.7%

10/25 Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 16.3%

1/15 Form 4 Merus N.V. For: Jan 13 Filed by: BVF INC/IL 13.8%

9/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.8%

4/3 Form 4 Merus N.V. For: Apr 01 Filed by: Throsby Mark 9.8%

11/4 Form 6-K Merus N.V. For: Nov 04 7.0%

4/24 Form SC 13G/A Merus N.V. Filed by: EcoR1 Capital, LLC 6.8%

3/19 Merus NV (NASDAQ: MRUS) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.3%

8/10 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%

4/16 Form 8-K Merus N.V. For: Apr 15 5.8%

Top News Decliners

10/27 Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions -16.2%

3/18 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -10.8%

3/10 Form 4 Merus N.V. For: Mar 04 Filed by: Throsby Mark -8.1%

4/29 Form 10-K/A Merus N.V. For: Dec 31 -7.5%

8/19 Form 6-K Merus N.V. For: Jun 30 -6.9%

4/30 Form POS AM Merus N.V. -6.6%

3/7 Merus NV (NASDAQ: MRUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -6.2%

5/20 Merus to Present at the RBC Capital Markets 2019 Healthcare Conference -5.9%

10/23 Merus NV (NASDAQ: MRUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.3%

4/6 Form 4 Merus N.V. For: Apr 02 Filed by: Throsby Mark -4.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day